We provide the latest news
from the world of economics and finance
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) reported the results from second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. Vanda expects to submit a NDA for tradipitant in the prevention of vomiting induced by motion to the FDA in the fourth quarter of 2024.
The Motion Serifos study was a multicenter double-blind, placebo-controlled study where 316 participants received tradipitant 170 mg, tradipitant 85 mg, or placebo. Both 170 mg and 85 mg tradipitant doses were shown to be superior to placebo in preventing vomiting.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.